Press releases
- Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
- Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
- Aurinia Pharmaceuticals Shareholder Urges Board of Directors to Take Action to Enhance Shareholder Value
- Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
- Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
- Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
- The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
- UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
- Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
- Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference
More ▼
Key statistics
As of last trade Aurinia Pharmaceuticals Inc (IKAP:DUS) traded at 4.79, 8.89% above its 52-week low of 4.40, set on Apr 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.80 |
---|---|
High | 4.80 |
Low | 4.79 |
Bid | 4.91 |
Offer | 5.01 |
Previous close | 4.84 |
Average volume | 78.44 |
---|---|
Shares outstanding | 143.02m |
Free float | 132.89m |
P/E (TTM) | -- |
Market cap | 749.42m USD |
EPS (TTM) | -0.4363 USD |
Data delayed at least 15 minutes, as of May 24 2024 11:31 BST.
More ▼